The U.S. and China restarted their trade talks, but signs are showing a comprehensive deal could be a long way off, if it happens at all.Marketsread more
The Swiss Federal Data Protection and Information Commissioner said on Tuesday it had not yet been contacted by Facebook about overseeing privacy protections for the Libra...Technologyread more
Stone, 66, a notorious Republican political operative who has described himself as a "dirty trickster," had previously been dressed down by the judge for his public remarks...Politicsread more
The Biden team's second quarter Federal Election Commission filing shows that the campaign wrote a check of just over $5,300 on June 28 to Sheehan Associates for "strategic...2020 Electionsread more
The speech comes as market participants are strongly anticipating a rate cut at the July 30-31 Federal Open Market Committee policy meeting.The Fedread more
Evans spoke Tuesday at CNBC's @Work Human Capital + Finance Conference in Chicago.At Workread more
But it's important to separate this very real threat from Thiel's specific allegations about Google, which were presented without proof, and from his claims that Google has...Technologyread more
In prepared remarks for a congressional hearing, Facebook says Instagram and WhatsApp have had a greater chance to thrive after merging.Technologyread more
Spotify stock plunged over 1% on a report that Apple is spending money to create its own original podcasts.Technologyread more
American consumers are flexing their muscles, and that's helping to save the economy from even slower growth as it faces what could be a protracted trade war.Market Insiderread more
The Dow slipped from a record high set earlier in the day after President Trump cast doubt on the trade progress between China and the U.S.US Marketsread more
The Senate Finance Committee's hearing with executives from pharmacy benefit managers will hopefully soon be followed by legislation to bring drug prices down and end the "secrecy" in the drug industry, Chairman Sen. Chuck Grassley told CNBC on Tuesday.
Executives from CVS Health, Cigna, OptumRx, a subsidiary of UnitedHealthcare, Prime Therapeutics and Humana, are scheduled to testify later in the day about high prescription drug costs. PBMs, sometimes referred to as "middlemen," negotiate discounts with manufacturers for insurance plans and employers.
Grassley and other lawmakers suspect these so-called backdoor deals between drug companies and pharmacy middlemen contribute to the high drug costs some consumers see at the pharmacy counter.
"There's a lot of secrecy. There's not a whole lot of understanding of the role they play," Grassley said in a "Squawk Box " interview. "Our goal is to end this secrecy, get to transparency. With transparency comes accountability."
The hearing Tuesday, led by Grassley, and Sen. Ron Wyden, D-Ore., marks the committee's third on drug prices this year. In late February, the committee heard testimony from executives of AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi.
For more on investing in health-care innovation, click here to join CNBC at our Healthy Returns Summit in New York City on May 21.
The pharma executives at the time pointed the blame at middlemen for pocketing discounts instead of passing them along to patients. The executives didn't commit to, or even suggest, lowering their list prices. Some referenced these prices as simply the price that's advertised, not what consumers actually pay.
High drug costs have become a rare bipartisan issue. President Donald Trump has made lowering prices one of the key issues of his administration, and Democrats are jockeying to prove they can lead reform.
Grassley said Tuesday there's already plenty of proposed legislation to bring down drug costs. He mentioned the CREATES Act, a bill introduced by Sen. Patrick Leahy, D-Vt., which aims to stop drugmakers from withholding samples of their medicines from generic manufacturers, thus increasing competition and lowering costs.